KUALA LUMPUR (Sept 22): Optimax Holdings Bhd has secured approval from the Securities Commission Malaysia (SC) for the proposed transfer to the Main Market of Bursa Malaysia Securities Bhd.

In a filing with Bursa Malaysia on Thursday (Sept 22), the private eye specialist provider which was listed on ACE market in August 2020, said the market capitalisation of the company is approximately RM410.89 million, based on the number of issued shares of Optimax, of 540 million shares.

The five-day volume weighted average market price of Optimax shares is 76 sen up to the latest practicable date.

The group via subsidiaries provides eye specialist services through its network of 13 eye specialist centres in Malaysia.

The eye specialist centres offer a range of treatments relating to eye and vision difficulties or impairment covering refractive error, cataracts, glaucoma, macular degeneration, diabetic retinopathy, and other eye diseases and disorders.

Other related services offered by Optimax’s eye specialist centres include eye examinations, sales of optical wear and food products, consumables from surgery and medical treatments, and procedures.

Optimax’s net profit surged more than two-fold to RM4.59 million in the second quarter ended June 30, 2022 (2QFY22), from the RM2.03 million recorded in the same quarter a year ago.

Revenue for the period also rose 53.4% to RM27.65 million from RM18.03 million, driven by an increase in the number of patients seeking treatments, including for refractive surgeries and cataract surgeries that had been postponed during the various movement control orders implemented within Malaysia.

Shares of Optimax settled unchanged at 75 sen on Thursday, for a market capitalisation of RM405 million.